ISRCTN33419176已完成未知
Cost utility of the latest antipsychotics in severe schizophrenia (CUtLASS): a multi-centre, randomised, controlled trial
Department of Health (UK)0 个研究点目标入组 227 人开始时间: 2003年4月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 227
研究概览
简要总结
2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16707074 HTA monograph
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Schizophrenics who are intolerant or resistant to usual treatment
排除标准
- •1. Substance use or organic illness as the main cause of psychotic symptoms.
- •2. History of neuroleptic malignant syndrome (NMS)
研究者
相似试验
已完成
不适用
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive DisorderDepressive Disorder, MajorNCT01145313Otsuka Pharmaceutical Development & Commercialization, Inc.501
已完成
不适用
Assessment of cost-effectiveness of the treatment of varicose veinsVaricose veins/ulcersCirculatory SystemISRCTN32956054Department of Health (UK)1,009
已完成
4 期
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of SchizophreniaSchizophreniaSchizoaffective DisorderNCT00007774US Department of Veterans Affairs600
撤回
4 期
Alleviating the Metabolic Side Effects of Antipsychotic MedicationsSchizophreniaNCT01567124Baker Heart and Diabetes Institute
已完成
不适用
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for SchizophreniaSchizophreniaNCT02192723Beijing HuiLongGuan Hospital550